Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.11Last Year’s EPS
-1.42Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 06, 2025
|% Change Since: 8.55%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong prescription growth, market positioning, and revenue performance for VOQUEZNA, but also addressed challenges such as potential legal issues with the FDA and anticipated Q1 revenue softness.Company Guidance
During the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call, the company provided comprehensive guidance for 2025, emphasizing their strategic focus on driving growth. Key metrics highlighted include achieving net revenues of $55.3 million for 2024, with expectations of reaching approximately $165 million in revenues for 2025. The company reported over 300,000 VOQUEZNA prescriptions filled since launch and commercial coverage for over 120 million lives. They anticipate non-GAAP operating expenses between $360 million and $390 million for 2025, driven by investments in expanded direct-to-consumer marketing and R&D, particularly for their new Phase 2 eosinophilic esophagitis trial. They also noted gross-to-net discounts approximating 57% for 2024 and maintained confidence in their coverage strategy, which allows for VOQUEZNA access after one generic PPI prescription. Phathom plans to continue leveraging its strong balance sheet, with $297 million in cash and additional funds available from their debt facility, to support these initiatives.VOQUEZNA FDA Approval and Market Positioning
Phathom Pharmaceuticals received FDA approval for VOQUEZNA for non-Erosive GERD, securing broad commercial access and launching a full-scale consumer campaign.
Strong Prescription Growth
Over 300,000 VOQUEZNA prescriptions filled, with a 110% growth in prescriptions over 17 weeks and a 70% increase in the fourth quarter compared to the third quarter.
Revenue and Financial Performance
Phathom reported net revenues of $29.7 million for Q4 2024, an 81% increase from the previous quarter, and $55.3 million for the full year 2024.
Commercial Coverage and Market Penetration
VOQUEZNA maintains over 80% commercial coverage, equating to more than 120 million lives.
Physician Adoption and Refill Rates
Over 20,000 physicians have written VOQUEZNA prescriptions, with a 75% refill rate among Q4 scripts, indicating strong physician and patient adoption.
---
PHAT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PHAT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 06, 2025 | $6.08 | $5.90 | -2.96% |
| Nov 07, 2024 | $18.00 | $18.50 | +2.78% |
| Aug 08, 2024 | $10.81 | $11.75 | +8.70% |
| May 09, 2024 | $10.10 | $10.09 | -0.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Phathom Pharmaceuticals (PHAT) report earnings?
Phathom Pharmaceuticals (PHAT) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Phathom Pharmaceuticals (PHAT) earnings time?
Phathom Pharmaceuticals (PHAT) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHAT EPS forecast?
PHAT EPS forecast for the fiscal quarter 2025 (Q1) is -1.11.
---